Evaluation of In-Vitro Dissolution and In-Vivo Absorption for Two Different Film-Coated Pellets of Clarithromycin |
Zhang Xiang-rong
(Department of Pharmacy, Laboratory of Drug Metabolism and Pharmacokinetics, Shenyang Pharmaceutical University)
Chen Xiao-yan (Department of Pharmacy, Laboratory of Drug Metabolism and Pharmacokinetics, Shenyang Pharmaceutical University) Hu Lian-Dong (Department of Pharmaceutics, Shenyang Pharmaceutical University) Tang Xing (Department of Pharmaceutics, Shenyang Pharmaceutical University) Li San-Ming (Department of Pharmaceutics, Shenyang Pharmaceutical University) Zhong Da-fang (Department of Pharmacy, Laboratory of Drug Metabolism and Pharmacokinetics, Shenyang Pharmaceutical University) |
1 | Chu, S. Y., Granneman, G. R., Pichotta, P. J., Decout, J. P., Girault, J., and Fourtilan, J. B., Effect of moderate or severe hepatic impairment on clarithromycin pharmacokinetics. J. Clin. Pharmacol., 33, 480-485 (1993) DOI ScienceOn |
2 | Nakagawa, Y., Itai, S., Yoshida, T., and Nagai, T., Physicochemical properties and stability in the acidic solution of a new macrolide antibiotic, clarithromycin, in comparision with erythromycin. Chem. Pharm. Bull., 40, 725-728 (1992) DOI ScienceOn |
3 | Sathe, P. M., Tsong Y., and Shah V. P., In-vitro dissolution profile comparision: statistics and analysis, model dependent approch. Pharm. Res., 13, 1799-1803 (1996) DOI ScienceOn |
4 | Amighi, K., Timmermans, J., Puigadevall, J., Baltes, E., and Moes, A. J., Peroral sustained-release film-coated pellets as a means to overcome physicochemical and biological drugrelated problems. I. In vitro development and eveluation. Drug Dev. Ind. Pharm., 24, 509-515 (1998) DOI ScienceOn |
5 | Chu, S. Y., Deaton, R., and Cavanaugh, J., Absolute bioavailability of clarithromycin after oral administration in humans. Antimicrob. Agents Chemother., 36, 1147-1150 (1992a) DOI ScienceOn |
6 | Grubel, P. and Cave, D. R., Factors affecting solubility and penetration of clarithromycin through gastric mucus. Alim. Pharmacol. Ther., 12, 569-576 (1998) DOI ScienceOn |
7 | Guay, D. R., Gustavson, L. E., Devcich, K. J., Zhang, J., Cao, G., and Olson, C. A., Pharmacokinetics and tolerabilty of extended-release clarithromycin. Clin. Ther., 23, 566-577 (2001) DOI ScienceOn |
8 | Bodmeier, R., Tableting of coated pellets. Eur. J. Pharm. Biopharm., 43, 1-8 (1997) DOI ScienceOn |
9 | Rodvold, K. A., Clinical pharmacokinetics of clatrithromycin. Clin. Pharmacokinet., 37, 385-398 (1999) DOI PUBMED ScienceOn |
10 | Erah, P. O., Barrett, D. A., and Shaw, P. N. Ion-pair highperformance liquid chromatographic assay method for the assessment of clarithromycin stability in aqueous solution and in gastric juice. J. Chromatogr. B., 682, 73-78 (1996) DOI ScienceOn |
11 | Sousa, J. J., Sousa, A., Moura, M. J., Podczeck, F., and Newton, J. M., The influence of core materials and film coating on the drug release from coated pellets. Int. J. Pharm., 233, 111-122 (2002) DOI PUBMED ScienceOn |
12 | Amidon, G. L., Lennemas, H., Shah, V. P., and Crison, J. R., A theoretical basis for a biopharmaceutical drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res., 12, 413-420 (1995) DOI ScienceOn |
13 | Chu, S. Y., Park, Y., Locke, C., Wilson, D. S., and Cavanaugh, J. C., Drug-food interaction potential of clarithromycin, a new macrolide antimicrobial. J. Clin. Pharmacol., 32, 32-36 (1992b) DOI |
14 | Dressman, J. B., Berardi, R. R., Dermentzoglou, L. C., Russell T. L., Schmaltz, S. P., Barnett, J. L., and Jarvenpaa, K. M., Upper gastrointestinal (GI) pH in young, healthy men and women. Pharm. Res., 7, 756-761 (1990) DOI ScienceOn |
15 | Arimori, K., Miyamoto, S., Fukuda, K., Nakamura, C., and Nakano, M., Characteristic difference in gastrointestinal excretion of clarithromycin and roxithromycin. Biopharm. Drug Dispos., 19, 433-438 (1998) DOI ScienceOn |